Clobetasol Propionate
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-23-D-0011
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
This procurement notice announces the award of a national contract (SPE2D2-23-D-0011) for the supply of Clobetasol Propionate 0.05% Solution, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505. The contract is managed by DLA Troop Support, a federal office responsible for ensuring the availability of critical medical and pharmaceutical supplies to support military and federal operations.
The primary objective of this procurement is to secure a reliable source of Clobetasol Propionate 0.05% Solution, a topical corticosteroid used for the treatment of various skin conditions. The scope of the contract encompasses the manufacturing and delivery of this pharmaceutical preparation, with the place of performance specified as Hauppauge, New York. This location serves as the central point for production or distribution activities related to the contract.
Key requirements for this contract include adherence to all applicable pharmaceutical manufacturing standards and regulations, ensuring product quality, safety, and efficacy. The contractor is expected to provide consistent and timely delivery of the specified solution to meet the needs of the federal government, with all deliverables conforming to the detailed specifications outlined in the contract documentation.
The contracting activity is overseen by DLA Troop Support, with primary and secondary points of contact provided for contractor inquiries: Keith Ryales ([email protected], 215-737-9199) and Jason Wray ([email protected], 215-737-0614). The notice remains active as of the posting date and is accessible via the official SAM.gov portal.
This award notice does not specify any set-aside requirements or special considerations such as small business preferences. Contractors interested in similar opportunities should ensure their capabilities align with pharmaceutical manufacturing standards and the ability to deliver high-quality products to federal specifications. The contract’s focus on a single, well-defined pharmaceutical product and its national scope suggest a need for robust production capacity and a proven track record in regulated pharmaceutical supply.
For further details, including attachments and official documentation, interested parties are encouraged to review the opportunity on SAM.gov using the provided link.
Documents6